Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells

Breast Cancer Research

Volumn 14, Issue 1, 2012, Pages

  Kumar, Anupam ^a   Xu, Jia ^a,b   Sung, Bokyung ^a   Kumar, Santosh ^a   Yu, Dihua ^a,b   Aggarwal, Bharat B ^a,b   Mehta, Kapil ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUTANT PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; GUANINE NUCLEOTIDE BINDING PROTEIN; HOMEODOMAIN PROTEIN; NUCLEAR PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TWIST; TWIST1 PROTEIN, HUMAN; ZEB1 PROTEIN, HUMAN;

ARTICLE; BINDING SITE; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER STEM CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; PROTEIN INDUCTION; WILD TYPE; BREAST TUMOR; CANCER INVASION; CELL MOTION; CELL SURVIVAL; CELL TRANSFORMATION; CHEMISTRY; DRUG RESISTANCE; ENZYME ACTIVE SITE; ENZYMOLOGY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; MAMMARY GLAND; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; PROTEIN BINDING; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CATALYTIC DOMAIN; CELL MOVEMENT; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP-BINDING PROTEINS; GUANOSINE TRIPHOSPHATE; HOMEODOMAIN PROTEINS; HUMANS; MAMMARY GLANDS, HUMAN; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; NF-KAPPA B; NUCLEAR PROTEINS; PHENOTYPE; PROTEIN BINDING; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TRANSCRIPTION FACTORS; TRANSGLUTAMINASES; TWIST TRANSCRIPTION FACTOR;

EID: 84855468654     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3085     Document Type: Article

References (40)

1. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890. 10.1016/j.cell.2009.11.007, 19945376.
2. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009, 119:1417-1419. 10.1172/JCI39675, 2689122, 19487817.
3. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119:1420-1428. 10.1172/JCI39104, 2689101, 19487818.
4. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
5. Mehta K, Fok J, Miller FR, Koul D, Sahin AA. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 2004, 10:8068-8076. 10.1158/1078-0432.CCR-04-1107, 15585642.
6. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 2007, 26:2459-2470. 10.1038/sj.onc.1210035, 17043648.
7. Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, Mehta K. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One 2010, 5:e13390. 10.1371/journal.pone.0013390, 2953521, 20967228.
8. Kumar A, Gao H, Xu J, Reuben J, Yu D, Mehta K. Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. PLoS One 2011, 6:e20701. 10.1371/journal.pone.0020701, 3110765, 21687668.
9. Kim SY. Transglutaminase 2 in inflammation. Front Biosci 2006, 11:3026-3035. 10.2741/2030, 16720373.
10. Siegel M, Khosla C. Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther 2007, 115:232-245. 10.1016/j.pharmthera.2007.05.003, 1975782, 17582505.
11. Fok JY, Ekmekcioglu S, Mehta K. Implications of tissue transglutaminase expression in malignant melanoma. Mol Cancer Ther 2006, 5:1493-1503. 10.1158/1535-7163.MCT-06-0083, 16818508.
12. Verma A, Wang H, Manavathi B, Fok JY, Mann A, Kumar R, Mehta K. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res 2006, 66:10525-10533. 10.1158/0008-5472.CAN-06-2387, 17079475.
13. Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G, Sood AK, Aggarwal BB, Krishnan S, Gelovani JG, Mehta K. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res 2008, 14:2476-2483. 10.1158/1078-0432.CCR-07-4529, 18413840.
14. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick ASM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 2008, 68:5849-5858. 10.1158/0008-5472.CAN-07-6130, 2547344, 18632639.
15. Yuan L, Behdad A, Siegel M, Khosla C, Higashikubo R, Rich KM. Tissue transglutaminase 2 expression in meningiomas. J Neurooncol 2008, 90:125-132. 10.1007/s11060-008-9642-1, 18587533.
16. Verma A, Mehta K. Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat 2007, 10:144-151. 10.1016/j.drup.2007.06.002, 17662645.
17. Yuan L, Choi K, Khosla C, Zheng X, Higashikubo R, Chicoine MR, Rich KM. Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol Cancer Ther 2005, 4:1293-1302. 10.1158/1535-7163.MCT-04-0328, 16170020.
18. Gundemir S, Johnson GV. Intracellular localization and conformational state of transglutaminase 2: implications for cell death. PLoS One 2009, 4:e6123. 10.1371/journal.pone.0006123, 2701606, 19568436.
19. Herman JF, Mangala LS, Mehta K. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 2006, 25:3049-3058. 10.1038/sj.onc.1209324, 16449978.
20. Mann AP, Verma A, Sethi G, Manavathi B, Wang H, Fok JY, Kunnumakkara AB, Kumar R, Aggarwal BB, Mehta K. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-κB in cancer cells: delineation of a novel pathway. Cancer Res 2006, 66:8788-8795. 10.1158/0008-5472.CAN-06-1457, 16951195.
21. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif 2003, 36:59-72. 10.1046/j.1365-2184.36.s.1.6.x, 14521516.
22. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991, 51(18 Suppl):5054s-5059s.
23. Cifone MA, Fidler IJ. Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc Natl Acad Sci USA 1980, 77:1039-1043. 10.1073/pnas.77.2.1039, 348419, 6928659.
24. Kim DS, Park SS, Nam BH, Kim IH, Kim SY. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-κB inactivation. Cancer Res 2006, 66:10936-10943. 10.1158/0008-5472.CAN-06-1521, 17108131.
25. Shao M, Cao L, Shen C, Satpathy M, Chelladurai B, Bigsby RM, Nakshatri H, Matei D. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res 2009, 69:9192-9201. 10.1158/0008-5472.CAN-09-1257, 19951993.
26. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454. 10.1038/nrc822, 12189386.
27. Mehta K, Kumar A, Kim HI. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer. Biochem Pharmacol 2010, 80:1921-1929. 10.1016/j.bcp.2010.06.029, 20599779.
28. Chhabra A, Verma A, Mehta K. Tissue transglutaminase promotes or suppresses tumors depending on cell context. Anticancer Res 2009, 29:1909-1919.
29. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011, 8:97-106. 10.1038/nrclinonc.2010.196, 21151206.
30. Colak G, Keillor JW, Johnson JVW. Cytosolic guanine nucleotide binding deficient form of transglutaminase 2 (R580A) potentiates cell death in oxygen glucose deprivation. PLoS One 2011, 6:e16665. 10.1371/journal.pone.0016665, 3031627, 21304968.
31. Begg GE, Carrington L, Stokes PH, Matthews JM, Wouters MA, Husain A, Lorand L, Iismaa SE, Graham RM. Mechanism of allosteric regulation of transglutaminase 2 by GTP. Proc Natl Acad Sci USA 2006, 103:19683-19688. 10.1073/pnas.0609283103, 1750866, 17179049.
32. Liu S, Cerione RA, Clardy J. Structural basis for the guanine nucleotide binding activity of tissue transglutaminase and its regulation of transamidation activity. Proc Natl Acad Sci USA 2002, 99:2743-2747. 10.1073/pnas.042454899, 122418, 11867708.
33. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003, 4:140-156. 10.1038/nrm1014, 12563291.
34. Creighton CJ, Chang JC, Rosen JM. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. Neoplasia 2010, 15:253-260.
35. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751. 10.1038/onc.2010.215, 3176718, 20531305.
36. Sarkar FH, Li Y, Wang Z, Kong D. NF-κB signaling pathway and its therapeutic implications in human diseases. Int Rev Immunol 2008, 27:293-319. 10.1080/08830180802276179, 18853341.
37. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2:301-310. 10.1038/nrc780, 12001991.
38. Min C, Eddy SF, Sherr DH, Sonenshein GE. NF-κB and epithelial to mesenchymal transition of cancer. J Cell Biochem 2008, 104:733-744. 10.1002/jcb.21695, 18253935.
39. Korsgren C, Cohen CM. Associations of human erythrocyte band 4.2: binding to ankyrin and to the cytoplasmic domain of band 3. J Biol Chem 1998, 263:10212-10218.
40. Mouro-Chanteloup I, Delaunay J, Gane P, Nicolas V, Johansen M, Brown EJ, Peters LL, Van Kim CL, Cartron JP, Colin Y. Evidence that the red cell skeleton protein 4.2 interacts with the Rh membrane complex member CD47. Blood 2003, 101:338-344. 10.1182/blood-2002-04-1285, 12393467.